UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Randomized phase II study of trabectedin (ET-743) given by two different dosing schedules in patients (pts) with leiomyosarcomas (LMS) or liposarcomas (LPS) refractory to conventional doxorubicin and ifosfamide chemotherapy

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.9000-9000

2004

Volltextzugriff (PDF)

Randomized phase II study of trabectedin (ET-743) given by two different dosing schedules in patients (pts) with leiomyosarcomas (LMS) or liposarcomas (LPS) refractory to conventional doxorubicin and ifosfamide chemotherapy

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.9000-9000

2004

Volltextzugriff (PDF)

Geriatric Assessment and Management in Cancer

Journal of clinical oncology, 2021-07, Vol.39 (19), p.2058-2067

2021

Volltextzugriff (PDF)

Three-Gene Immunohistochemical Panel Adds to Clinical Staging Algorithms to Predict Prognosis for Patients With Esophageal Adenocarcinoma

Journal of clinical oncology, 2013-04, Vol.31 (12), p.1576-1582

2013

Volltextzugriff (PDF)

Participation of older patients with advanced gastroesophageal cancer in clinical trials: A systematic review of age-restrictive inclusion criteria over the last 25 years

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e24017-e24017

2021

Volltextzugriff (PDF)

Combined treatment using the anti-p53 drug, APR-246 and eribulin: Synergistic growth inhibition in p53-mutated breast cancer cells

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e14098-e14098

2017

Volltextzugriff (PDF)

BRCA1/BRCA2 predictive genetic testing in an Irish population: A missed opportunity

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e13530-e13530

2018

Volltextzugriff (PDF)

The vitamin D receptor as a target for the treatment of breast cancer: Studies with the low calcemic vitamin D analog, inecalcitol

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e12011-e12011

2016

Volltextzugriff (PDF)

Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Prelinical investigation with the anti-p53 drug, APR-246

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.1082-1082

2016

Volltextzugriff (PDF)

The vitamin D receptor: A therapeutic target for the treatment of breast cancer?

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.534-534

2015

Volltextzugriff (PDF)

Targeting mutant p53 with PK11007: A new approach for the treatment of patients with triple-negative breast cancer?

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e14099-e14099

2017

Volltextzugriff (PDF)

PRIMA-1 MET (APR-246): A novel targeted therapy for triple negative breast cancer?

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e12072-e12072

2015

Volltextzugriff (PDF)

Mutant p53: A therapeutic target for the treatment of triple-negative breast cancer?

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.1118-1118

2014

Volltextzugriff (PDF)

Neratinib to inhibit the growth of triple-negative breast cancer cells

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.1099-1099

2015

Volltextzugriff (PDF)

The clinical impact of early immunological responses in human HER2-positive breast cancers on responsiveness to trastuzumab-based therapy

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.587-587

2016

Volltextzugriff (PDF)

Impact of somatic PIK3CA and ERBB family mutations on pathological complete reponse (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.591-591

2016

Volltextzugriff (PDF)

ADAM17 as a novel therapeutic target for HER2-positive breast cancer

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.622-622

2012

Volltextzugriff (PDF)

Preclinical studies with neratinib in triple-negative breast cancer

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.1054-1054

2013

Volltextzugriff (PDF)

Lapatinib-induced senescent-like phenotype in HER2-positive breast cancer cells

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.583-583

2011

Volltextzugriff (PDF)

ADAMs as new therapeutic targets for triple-negative breast cancer

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.1062-1062

2011

Volltextzugriff (PDF)

Activity of dasatinib with chemotherapy in triple-negative breast cancer cells

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.e14605-e14605

2009

Volltextzugriff (PDF)

Identification of predictive biomarkers for dasatinib treatment of metastatic melanoma

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.8578-8578

2011

Volltextzugriff (PDF)

Open-label, multicenter, phase Ib, dose-escalation study of oral lapatinib (L) in combination with docetaxel (D) and trastuzumab (T) in untreated HER2-overexpressing (HER+) metastatic breast cancer (MBC)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.1049-1049

2010

Volltextzugriff (PDF)

HSP90 inhibition in HER2-positive breast cancer cells

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.e14573-e14573

2009

Volltextzugriff (PDF)

Effect of trastuzumab on antibody-dependent cellular cytotoxicity (ADCC) in HER2 nonamplified (non-amp) breast cancer (BC) cells

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.659-659

2010

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Clinical Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(32)

Sprache

Englisch
(32)
Norwegisch
(1)

Erscheinungsjahr

n.n

Kollektion

1 weiteren anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Randomized phase II study of trabectedin (ET-743) given by two different dosing schedules in patients (pts) with leiomyosarcomas (LMS) or liposarcomas (LPS) refractory to conventional doxorubicin and ifosfamide chemotherapy

Randomized phase II study of trabectedin (ET-743) given by two different dosing schedules in patients (pts) with leiomyosarcomas (LMS) or liposarcomas (LPS) refractory to conventional doxorubicin and ifosfamide chemotherapy

Geriatric Assessment and Management in Cancer

Three-Gene Immunohistochemical Panel Adds to Clinical Staging Algorithms to Predict Prognosis for Patients With Esophageal Adenocarcinoma

Participation of older patients with advanced gastroesophageal cancer in clinical trials: A systematic review of age-restrictive inclusion criteria over the last 25 years

Combined treatment using the anti-p53 drug, APR-246 and eribulin: Synergistic growth inhibition in p53-mutated breast cancer cells

BRCA1/BRCA2 predictive genetic testing in an Irish population: A missed opportunity

The vitamin D receptor as a target for the treatment of breast cancer: Studies with the low calcemic vitamin D analog, inecalcitol

Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Prelinical investigation with the anti-p53 drug, APR-246

The vitamin D receptor: A therapeutic target for the treatment of breast cancer?

Targeting mutant p53 with PK11007: A new approach for the treatment of patients with triple-negative breast cancer?

PRIMA-1 MET (APR-246): A novel targeted therapy for triple negative breast cancer?

Mutant p53: A therapeutic target for the treatment of triple-negative breast cancer?

Neratinib to inhibit the growth of triple-negative breast cancer cells

The clinical impact of early immunological responses in human HER2-positive breast cancers on responsiveness to trastuzumab-based therapy

Impact of somatic PIK3CA and ERBB family mutations on pathological complete reponse (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies

ADAM17 as a novel therapeutic target for HER2-positive breast cancer

Preclinical studies with neratinib in triple-negative breast cancer

Lapatinib-induced senescent-like phenotype in HER2-positive breast cancer cells

ADAMs as new therapeutic targets for triple-negative breast cancer

Activity of dasatinib with chemotherapy in triple-negative breast cancer cells

Identification of predictive biomarkers for dasatinib treatment of metastatic melanoma

Open-label, multicenter, phase Ib, dose-escalation study of oral lapatinib (L) in combination with docetaxel (D) and trastuzumab (T) in untreated HER2-overexpressing (HER+) metastatic breast cancer (MBC)

HSP90 inhibition in HER2-positive breast cancer cells

Effect of trastuzumab on antibody-dependent cellular cytotoxicity (ADCC) in HER2 nonamplified (non-amp) breast cancer (BC) cells

Aktive Filter

Suchergebnisse filtern